FDA Grants Emergency Authorization for Novavax COVID-19 Vaccine

A vial of the Phase 3 Novavax coronavirus vaccine is seen ready for use in the trial at St. George's University hospital in London on Oct. 7, 2020. Alastair Grant/AP Photo

The Food and Drug Administration (FDA) on Wednesday issued an emergency use authorization for Novavax’s protein-based COVID-19 vaccine.

“Authorizing an additional COVID-19 vaccine expands the available vaccine options for the prevention of COVID-19, including the most severe outcomes that can occur such as hospitalization and death,” FDA Commissioner Robert Califf said in a statement.